PDCD1 and neoplasm: PD-1 is expressed during T cell activation and engages its ligands PD-L1 and PD-L2, thus inhibiting effective T cell cytotoxicity resulting in poor anti-tumor immunity (Greenwald et al., 2005; Sun et al., 2018).